In the high-stakes world of oncology, time is the most precious resource. For patients recovering from cancer treatment, the period following surgery or chemotherapy is often defined by a quiet, agonizing uncertainty: the question of whether a microscopic trace of disease remains, invisible to standard imaging, poised to return.
On October 26, 2026, a major technological leap occurred that promises to shorten that window of uncertainty. Abbott launched the next-generation Oncodetect test, a molecular residual disease (MRD) assay that represents the culmination of over a decade of rigorous research at the Broad Institute of MIT and Harvard. By utilizing an ultra-sensitive technology known as MAESTRO—developed by a team led by Viktor Adalsteinsson—this test can detect cancer-derived DNA at concentrations as low as one part per million, offering clinicians a window into a patient’s molecular status that was previously inaccessible.
The Genesis of an Idea: From Graduate Studies to Clinical Reality
The story of Oncodetect begins not in a boardroom, but in the laboratory. Over ten years ago, Viktor Adalsteinsson joined the Broad Institute’s Cancer Program with a singular, ambitious objective: to revolutionize how we detect and monitor cancer. At the time, the limitations of liquid biopsy—a technique that relies on isolating circulating tumor DNA (ctDNA) from a simple blood draw—were significant. The primary challenge was the "signal-to-noise" ratio; cancer DNA is often vastly outnumbered by the DNA shed by healthy cells.
Adalsteinsson, who earned his PhD in chemical engineering at MIT in 2015, cut his teeth in the laboratory of Chris Love, where he pioneered early methods for sequencing single circulating tumor cells. Upon establishing his own lab at the Broad, he pivoted toward the broader challenge of ctDNA. He realized that if he could isolate and identify the unique genetic fingerprints of a tumor, he could track its potential return with unprecedented accuracy.
This research trajectory led to the development of MAESTRO, an acronym for "minor allele enriched sequencing through recognition oligonucleotides." Unlike earlier generation tests that scanned for a limited subset of mutations, MAESTRO performs a whole-genome analysis, tracking up to 5,000 patient-specific cancer mutations. This depth of coverage is what allows the test to reach the remarkable threshold of one part per million, providing a granular view of molecular residual disease.
A Chronology of Innovation and Collaboration
The journey from a laboratory concept to a commercially available diagnostic tool was marked by deliberate, strategic milestones:
- 2015–2018: Foundation Building: Adalsteinsson establishes his lab at the Broad Institute, focusing on the mechanics of tumor evolution and the persistence of ctDNA following therapeutic intervention.
- 2019–2022: The Birth of MAESTRO: The team develops the MAESTRO platform, demonstrating that they could distinguish rare cancer-derived mutations from healthy genetic background noise with high precision.
- 2023: Strategic Partnership: Recognizing the need for commercial scalability and clinical validation, the Broad Institute enters into a research collaboration with Exact Sciences, licensing the MAESTRO technology to leverage the company’s diagnostic infrastructure.
- Early 2026: Consolidation: Abbott acquires Exact Sciences, inheriting the collaborative partnership with the Broad Institute and accelerating the final stages of the Oncodetect rollout.
- October 26, 2026: Clinical Launch: The next-generation Oncodetect test is officially launched, marking the first time the MAESTRO-powered technology is accessible to the broader medical community.
Technical Superiority: Breaking the Sensitivity Barrier
The leap from the first-generation Oncodetect test to the current iteration is substantial. While the original version focused on a panel of up to 200 mutations, the new version—powered by MAESTRO—tracks up to 5,000 mutations across the entire genome.
In clinical practice, sensitivity is the primary arbiter of success. Because molecular residual disease often manifests as a few strands of DNA among millions, a test that is not sufficiently sensitive will produce a "false negative," providing the patient with a false sense of security. By pushing detection limits to one part per million (under high-input conditions), Oncodetect allows oncologists to see the "smoke" of a tumor long before the "fire" of a recurrence appears on a CT or PET scan.
This technological edge does not stop at detection. The data provided by the test allows for more personalized treatment pathways. If a recurrence is detected at the molecular level, doctors may be able to intervene with targeted therapies or immunotherapy earlier, potentially preventing the development of overt, metastatic disease.
The Ecosystem of Success: Official Perspectives
The launch of Oncodetect is being hailed as a triumph of the "Broad ecosystem," a unique environment that facilitates the intersection of academic research, hospital clinical data, and private industry.
Todd Golub, director of the Broad Institute, who worked alongside Adalsteinsson to establish the Gerstner Center for Cancer Diagnostics, emphasized the difficulty of this path. "When we started the Broad, the idea from the very beginning was that our genomics research would benefit patients," Golub said. "It’s easy to say that, but it’s a long and arduous road. When it actually happens, it’s very satisfying and a great validation of the multidisciplinary, collaborative nature of this place."
For the industry partners involved, the focus remains on the tangible impact for the patient. "The promise of innovation is ultimately measured by what it can mean for patients," noted Jorge Garces, divisional vice president of R&D at Abbott. "Working with the Broad, we were able to take an extraordinary scientific innovation in MAESTRO and translate it into a test designed to give physicians more information about what may remain during and after cancer treatment."
The Gerstner Family Foundation, which has provided long-standing support for the Gerstner Center, highlighted the importance of this translational pipeline. Elizabeth Gerstner, chair of the Foundation, stated: "We believe in their ability not only to advance groundbreaking science, but to translate discoveries into better care for patients. The launch of Oncodetect demonstrates the power of that commitment."
Implications for the Future of Oncology
The introduction of Oncodetect is merely the opening chapter of a broader shift in how we monitor cancer. Adalsteinsson and his team at the Gerstner Center are already looking ahead to the next frontier of liquid biopsy: the "priming agent."
Currently, the amount of tumor DNA in the blood is limited by how quickly the body clears it. Adalsteinsson’s team is developing diagnostic drugs designed to slow this clearance, effectively acting as a "magnifying glass" for the bloodstream. By keeping tumor DNA present for longer, these agents could further enhance the sensitivity of liquid biopsy tests, making the detection of even the most elusive cancer cells a routine procedure.
Furthermore, the methodologies developed alongside MAESTRO—such as CODEC and Methyl CODEC—are setting new standards for the accuracy of DNA sequencing. These methods allow researchers to distinguish between true mutations and the errors that often plague high-throughput sequencing, ensuring that the results provided to clinicians are as accurate as they are sensitive.
Conclusion: A New Standard of Care
The launch of the next-generation Oncodetect test is a significant milestone in the fight against cancer. By closing the gap between the end of treatment and the potential for recurrence, it offers patients and their families the most valuable commodity of all: actionable information.
For Viktor Adalsteinsson, the success of the technology is deeply personal. Having spent his career focused on the intersection of engineering and biology to save lives, he sees the launch not as an end point, but as a proof of concept. "I always knew that I wanted to pursue approaches that could improve the lives of cancer patients," Adalsteinsson said. "MAESTRO pushes the limits for molecular residual disease detection. We’re thrilled to see that this technology will reach patients to inform more precise care."
As diagnostic tools become more precise, the definition of "cured" or "in remission" is likely to evolve. With the integration of technologies like Oncodetect into clinical practice, the oncology field is moving closer to a future where cancer is treated not as a sudden, catastrophic event, but as a manageable condition, monitored with the precision of a watchmaker and addressed before it can gain a foothold in the patient’s body. The collaboration between the Broad Institute and Abbott serves as a blueprint for how academic brilliance, when paired with industrial scale, can turn the tide of human disease.
About the Author
